Physician profile
Hubert H Pham
NPI 1578880902
$3,587.29
in general payments reported to CMS, 2019-2025
22 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.55 · 2021: $297 · 2022: $972 · 2023: $691 · 2024: $769 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,231.15 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,007.52 | 2019-2025 | Clareon, Tryptyr, Clareon Panoptix Pro |
| Rxsight INC | $435.04 | 2022-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| New World Medical,INC. | $331.44 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $314.99 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $270.93 | 2022-2025 | Photrexa, Photrexa Viscous and Photrexa, Idosetr |
| Biotissue Holdings INC. | $235.29 | 2024-2025 | |
| Coopervision INC. | $143.27 | 2024 | Misight Contact Lens |
| Bausch & Lomb Americas INC. | $127.65 | 2022-2024 | Miebo, Xiidra, Doctors Allergy Formula |
| Sun Pharmaceutical Industries INC. | $122.42 | 2023-2024 | Cequa |
| Apellis Pharmaceuticals, INC. | $112.50 | 2023 | Syfovre |
| Astellas Pharma US INC | $100.00 | 2024 | Izervay |
| Dompe US, INC. | $90.48 | 2022-2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $51.44 | 2022-2025 | Veritas Vision System, Tecnis Simplicity |
| Novartis Pharmaceuticals Corporation | $39.82 | 2022 | |
| Oyster Point Pharma, INC. | $35.97 | 2022-2024 | Tyrvaya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $31.75 | 2022 | |
| Glaxosmithkline, LLC. | $31.04 | 2022 | |
| Harrow Eye, LLC | $27.18 | 2025 | Vevye |
| Thea Pharma INC. | $23.81 | 2024 | Iyuzeh |
| Horizon Therapeutics Plc | $20.56 | 2022 | |
| Abbvie INC. | $19.68 | 2023 | |
| Carl Zeiss Meditec, INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hubert Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.